ClinicalTrials.gg

Program

nerandomilast

Also written as “BI 1015550”, “Nerandomilast” and “Nerandomilast formulation 1”.

Its studies are mostly in Lung Diseases, Interstitial · Idiopathic Pulmonary Fibrosis · Myositis · Scleroderma, Systemic · Amyotrophic Lateral Sclerosis, led by 2 companies.

Furthest: phase 3, since Apr 4, 202235 company-led studies, 8 open or runningNext primary completion: Apr 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim347 open or runningphase 3since Apr 4, 2022May 7, 2012Apr 15, 2027phase 3 · NCT06806592
Gipfel Life Sciences11 open or runningphase 3since Jan 2, 2026Jan 2, 2026Jun 30, 2027phase 3 · NCT07321860

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since May 7, 2012.

  1. Nov 15, 2023Phase 1 study in HealthyBoehringer Ingelheim · NCT06139302 · 12 enrolled · Japan
  2. Jan 25, 2024Phase 3 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT06238622 · 1,666 enrolled · United States, Argentina, Australia and more
  3. Jan 29, 2024Phase 2 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT06241560 · 20 enrolled · United States, Georgia
  4. Apr 29, 2024Phase 1 study in HealthyBoehringer Ingelheim · NCT06393127 · 64 enrolled · Germany
  5. May 7, 20242 phase 1 studies in HealthyBoehringer Ingelheim · NCT06408870, NCT06415045
  6. Oct 1, 2024Phase 1 study in HealthyBoehringer Ingelheim · NCT06624072 · 15 enrolled · Germany
  7. Jan 28, 2025Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT06806592 · 414 enrolled · United States, Australia, Austria and more
  8. Jul 22, 20252 phase 1 studies in HealthyBoehringer Ingelheim · NCT07081932, NCT07100964
  9. Sep 30, 2025Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT07201922 · 80 planned · United States, Argentina, Australia and more
  10. Jan 2, 2026Gipfel Life Sciences's first study: phase 3 study in Amyotrophic Lateral SclerosisNew to Gipfel Life SciencesGipfel Life Sciences · NCT07321860 · 60 planned
  11. Jan 23, 2026Phase 3 study in Fibrosing Interstitial Lung DiseaseBoehringer Ingelheim · NCT07366034 · 35 planned · United States, Argentina, Australia and more
  12. Mar 23, 2026Phase 3 study in Scleroderma, SystemicBoehringer Ingelheim · NCT07497087 · 448 planned · United States, Argentina, Australia and more
  13. Apr 15, 2026Phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT07540988 · 466 planned · United States, Argentina, Australia and more
  14. Aug 24, 2026Phase 3 study in MyositisBoehringer Ingelheim · NCT07789015 · 270 planned · United States, Argentina, Australia and more

Ahead

  1. Apr 15, 2027Primary completion: phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT06806592
  2. Apr 28, 2027Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisBoehringer Ingelheim · NCT06238622
  3. Jun 30, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisGipfel Life Sciences · NCT07321860
  4. Dec 5, 2028Primary completion: phase 3 study in Lung Diseases, InterstitialBoehringer Ingelheim · NCT07540988

TargetBeta

PDE4B →read by rule
“Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades.”study text, by rule · the study

Other programs on PDE4B

ProgramCompanyFurthest phaseStudies
RoflumilastruleAstraZenecaphase 461
apremilastruleAmgenphase 448
ensifentrineruleMerckphase 317
difamilastruleOtsukaphase 316
tanimilastruleChiesi Farmaceuticiphase 315

Studies

All 35 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07789015Myositis · United States, Argentina, Australia and more3Not yet recruitingBoehringer IngelheimMar 21, 2030270
NCT07540988Lung Diseases, Interstitial · United States, Argentina, Australia and more3RecruitingBoehringer IngelheimDec 5, 2028466
NCT07497087Scleroderma, Systemic · United States, Argentina, Australia and more3RecruitingBoehringer IngelheimFeb 26, 2030448
NCT07366034Fibrosing Interstitial Lung Disease · United States, Argentina, Australia and more3RecruitingBoehringer IngelheimApr 27, 202935
NCT07321860Amyotrophic Lateral Sclerosis3Not yet recruitingGipfel Life SciencesJun 30, 202760
NCT07201922Lung Diseases, Interstitial · United States, Argentina, Australia and more3RecruitingBoehringer IngelheimMay 14, 202980
NCT07100964Healthy · Germany1CompletedBoehringer IngelheimSep 20, 202516
NCT07081932Healthy · Germany1CompletedBoehringer IngelheimSep 27, 202516
NCT06806592Lung Diseases, Interstitial · United States, Australia, Austria and more3Active, not recruitingBoehringer IngelheimApr 15, 2027414
NCT06624072Healthy · Germany1CompletedBoehringer IngelheimNov 22, 202415
NCT06415045Healthy · Germany1CompletedBoehringer IngelheimJul 24, 202418
NCT06408870Healthy · Germany1CompletedBoehringer IngelheimAug 28, 202464
NCT06393127Healthy · Germany1CompletedBoehringer IngelheimSep 10, 202464
NCT06241560Idiopathic Pulmonary Fibrosis · United States, Georgia2CompletedBoehringer IngelheimAug 5, 202620
NCT06238622Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more3Active, not recruitingBoehringer IngelheimApr 28, 20271,666
NCT06139302Healthy · Japan1CompletedBoehringer IngelheimFeb 7, 202412
NCT06107036Healthy · United Kingdom1CompletedBoehringer IngelheimJul 25, 202446
NCT06070610Healthy · Germany1CompletedBoehringer IngelheimDec 14, 202314
NCT05718648Renal Insufficiency · Germany1CompletedBoehringer IngelheimAug 15, 202326
NCT05707403Healthy · Netherlands1CompletedBoehringer IngelheimMar 28, 20238
NCT05661344Hepatic Insufficiency · Germany1CompletedBoehringer IngelheimSep 13, 202328
NCT05633862Healthy · China1CompletedBoehringer IngelheimMar 16, 202324
NCT05550636Healthy · Germany1CompletedBoehringer IngelheimDec 19, 202215
NCT05428436Healthy · Germany1CompletedBoehringer IngelheimSep 30, 202224
NCT05321082Lung Diseases, Interstitial · United States, Argentina, Australia and more3CompletedBoehringer IngelheimDec 18, 20241,178
NCT05321069Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more3CompletedBoehringer IngelheimAug 16, 20241,177
NCT04771286Healthy · Netherlands1CompletedBoehringer IngelheimMay 17, 20216
NCT04419506Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more2CompletedBoehringer IngelheimOct 6, 2021147
NCT03542344Healthy · Japan1CompletedBoehringer IngelheimAug 24, 201816
NCT03422068Idiopathic Pulmonary Fibrosis · Denmark, Finland, Germany and more1CompletedBoehringer IngelheimJul 1, 201915
NCT03403439Healthy · Germany1CompletedBoehringer IngelheimJul 20, 201816
NCT03302078Healthy · Germany1CompletedBoehringer IngelheimDec 13, 201712
NCT03230487Healthy · Germany1CompletedBoehringer IngelheimJan 16, 201842
NCT01835899Healthy · Germany1CompletedBoehringer IngelheimJun 201324
NCT01594515Healthy · Germany1CompletedBoehringer IngelheimSep 201270

How it is read

Names in the registry

  • “BI 1015550”, 27 entries
  • “Nerandomilast”, 10 entries
  • “Nerandomilast formulation 1”, 1 entry
  • “Nerandomilast formulation 2”, 1 entry
  • “Nerandomilast 18 mg - adult formulation”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.